A family of compounds capable of inhibiting the activity of prenyl transferases. The compounds are covered by either of the two following formulas ##STR1## Each of the R groups is defined in the disclosure.
|
1. A compound of the formula I or formula ii ##STR4## wherein R1 is N(R10)(R11);
R2 is thio lower alkyl; each of R3 and R5, independently, is CH2 or C(O); R4 is thio lower alkyl, wherein the free thio groups of R2 and R4 form a disulfide bond; R6 is a residue of a natural or synthetic α-amino acid R7 is a residue of a natural or synthetic α-amino acid; R8 is OH or lower alkoxy, or, together with R7, forms homoserinelactone; each of R9, R10, R11, independently, is H or lower alkyl; R12 is a substituted or unsubstituted moiety selected from cycloalkyl, cycloalkyl lower alkyl, aryl, aryl lower alkyl, heterocycle, and heterocycle lower alkyl, wherein the substituent is lower alkyl, aryl, halo, lower alkoxy, or C(O)--R7 --R8 ; R13 is lower alkyl, aryl, or aryl lower alkyl; R18 is H or, together with R9, forms --CH2 CH2 --;
or a pharmaceutically acceptable salt thereof. 2. A compound of
3. A compound of
4. A compound of
R6 is --N(R14)CH(R15)C(O)-- where R14 is H or lower alkyl, and R15 is a substituted or unsubstituted moiety selected from lower alkyl, aryl, aryl lower alkyl, heterocycle, and heterocycle lower alkyl, in which said substituent is lower alkyl, halo, or lower alkoxy, or R15, together with N(R14)C attached thereto, form a heterocycle; R7 is --N(R16)CH(R17)C(O)-- where R16 is H or lower alkyl; and R17 is (CH2)m S(O)n CH3 where m is 1-6 and n is 0-2, or is a substituted or unsubstituted moiety selected from lower alkyl and thio lower alkyl, where said substituent is C(O)N(R10)(R11); and R8 is OH or lower alkoxy;
or a pharmaceutically acceptable salt thereof. 5. A compound of
R2 is CH2 SH; and R4 is C(CH3)2 SH or CH2 SH;
in which the free thio groups of R2 and R4 form a disulfide bond; or a pharmaceutically acceptable salt thereof. 6. A compound of
7. A compound of
R1 is NH2 ; R3 is CH2 ; R5 is C(O); and R8 is OH or OCH3 ;
or a pharmaceutically acceptable salt thereof. 8. A compound of
R2 is CH2 SH; and R4 is C(CH3)2 SH or CH2 SH;
in which the free thio groups of R2 and R4 form a disulfide bond; or a pharmaceutically acceptable salt thereof. 9. A compound of
10. A compound of
R1 is NH2 ; R3 is CH2 ; R5 is C(O); R9 is H; and R12 is substituted or unsubstituted phenyl or benzyl, where said substituent is lower alkyl or halo; or a pharmaceutically acceptable salt thereof.
12. A method of treating tumors or restenosis in a subject in need of said treatment, which comprises administering to said subject a therapeutically effective amount of the compound or salt of
13. A method of treating tumors or restenosis in a subject in need of said treatment, which comprises administering to said subject a therapeutically effective amount of a compound or salt thereof according to
14. A pharmaceutical composition comprising a compound of
|
|||||||||||||||||||||||||||||||
The Ras family of proteins are important in the signal transduction pathway modulating cell growth. The protein is produced in the ribosome, released into the cytosol, and post-translationally modified. The first step in the series of post-translational modifications is the alkylation of Cys168 with farnesyl or geranylgeranyl pyrophosphate in a reaction catalyzed by prenyl transferase enzymes such as farnesyl tranferase and geranylgeranyl transferase (Hancock, J. F., et al., Cell 57:1167-1177 (1989)). Subsequently, the three C-terminal amino acids are cleaved (Gutierrez, L., et al., EMBO J. 8:1093-1098 (1989)), and the terminal Cys is converted to a methyl ester (Clark, S., et al., Proc. Nat'l Acad. Sci. (USA) 85:4643-4647 (1988)). Some forms of Ras are also reversibly palmitoylated on cysteine residues immediately N-terminal to Cys168 (Buss, J. E., et al., Mol. Cell. Biol. 6:116-122 (1986)). It is believed that these modifications increase the hydrophobicity of the C-terminal region of Ras, causing it to localize at the surface of the cell membrane. Localization of Ras to the cell membrane is necessary for signal transduction (Willumsen, B. M., et al., Science 310:583-586 (1984)).
Oncogenic forms of Ras are observed in a relatively large number of cancers including over 50 percent of colon cancers and over 90 percent of pancreatic cancers (Bos, J. L., Cancer Research 49:4682-4689 (1989)). These observations suggest that intervention in the function of Ras mediated signal transduction may be useful in the treatment of cancer.
Previously, it has been shown that the C-terminal tetrapeptide of Ras has the "CAAX" motif (wherein C is cysteine, A is an aliphatic amino acid, and X is any amino acid). Tetrapeptides having this structure have been shown to be inhibitors of prenyl transferases (Reiss, et al., Cell 62:81-88 (1990)). Poor potency of these early farnesyl transferase inhibitors has prompted the search for new inhibitors with more favorable pharmacokinetic behavior (James, G. L., et al., Science 260:1937-1942 (1993); Kohl, N. E., et al., Proc. Nat'l Acad. Sci. USA 91:9141-9145 (1994); deSolms, S. J., et al., J. Med. Chem. 38:3967-3971 (1995); Nagasu, T, et al., Cancer Research 55:5310-5314 (1995); Lerner, E. C., et al., J. Biol. Chem. 270:26802-26806 (1995); Lerner, E. C., et al., J. Biol. Chem. 270:26770 (1995); and James, et al., Proc. Natl. Acad. Sci. USA 93:4454 (1996)).
Recently, it has been shown that a prenyl transferase inhibitor can block growth of Ras-dependent tumors in nude mice (Kohl, N. E., et al., Proc. Nat'l Acad. Sci. USA 91:9141-9145 (1994)). In addition, it has been shown that over 70 percent of a large sampling of tumor cell lines are inhibited by prenyl transferase inhibitors with selectivity over non-transformed epithelial cells (Sepp-Lorenzino, I, et al., Cancer Research, 55:5302-5309 (1995)).
In one aspect, the invention features a compound of formula I or formula II ##STR2## wherein R1 is N(R10) (R11);
R2 is thio lower alkyl;
each of R3 and R5, independently, is CH2 or C(O);
R4 is substituted or unsubstituted thio lower alkyl, wherein said substituent is CH2 NHC(O)R13 and said substituent is attached to said thio group;
R6 is a residue of a natural or synthetic α-amino acid;
R7 is a residue of a natural or synthetic α-amino acid;
R8 is OH or lower alkoxy, or, together with R7, forms homoserinelactone;
each of R9, R10 and R11, independently, is H or lower alkyl;
R12 is substituted or unsubstituted cycloalkyl, cycloalkyl lower alkyl, aryl, aryl lower alkyl, heterocycle, or heterocycle lower alkyl, wherein said substituent is lower alkyl, aryl, halo, lower alkoxy, or C(O)--R7 --R8 ;
R13 is lower alkyl, aryl, or aryl lower alkyl; R18 is H or, together with R9, forms CH2 CH2 ; provided if R4 is unsubstituted thio lower alkyl, the free thio group of R2 and the free thio group of R4 may form a disulfide bond; or a pharmaceutically acceptable salt thereof.
In one embodiment, the compound is of formula I where R6 is --N(R14)CH(R15)C(O)-- where R14 is H or lower alkyl, and R15 is substituted or unsubstituted lower alkyl, aryl, aryl lower alkyl, heterocycle, or heterocycle lower alkyl where said substituent is lower alkyl, halo, or lower alkoxy, or where R15, together with NR14 C attached thereto, form heterocycle; and R7 is --N(R16)CH(R17)C(O)-- where R16 is H or lower alkyl, and R17 is (CH2)m S(O)n CH3 or substituted or unsubstituted lower alkyl, thio lower alkyl, where said substituent is C(O)N(R10) (R11), m is 1-6, n is 0-2, and R8 is OH or lower alkoxy. In this embodiment, R2 can be CH2 SH; R4 can be C(CH3)2 SH or CH2 SH wherein the free thio group of R2 and the free thio group of R4 form a disulfide bond; R15, together with NR14 C attached thereto, can form heterocycle; R16 can be H; and R17 can be (CH2)2 S(O)n CH3 ; furthermore, R1 can be NH2; R3 can be CH2 ; R5 can be CO; and R8 can be OH or OCH3. In the same embodiment, R2 can be (CH2)SH; R4 can be C(CH2)2 SCH2 NHCOCH3 or CH2 SCH2 NHCOCH3 ; R15, together with NR14 C attached thereto, can form heterocycle; R16 can be H, and R17 can be (CH2)2 S(O)n CH3 ; furthermore, R1 is NH2; R3 is CH2; R5 is C(O); and R8 is OH or OCH3.
In another embodiment, the compound is of formula II, wherein R2 is CH2 SH; R4 is C(CH3)2 SH or CH2 SH wherein the free thio group of R2 and the free thio group of R4 form a disulfide bond; R12 is substituted or unsubstituted aryl or aryl lower alkyl, and R18 is H. In this embodiment, R, can be NH2; R3 can be CH2 ; R5 can be C(O); R9 can be H; and R12 can be substituted or unsubstituted phenyl or benzyl, wherein said substituent is lower alkyl or halo.
In a still further embodiment, R2 is (CH2)SH; R4 is C(CH2)2 SCH2 NHCOCH3 or CH2 SCH2 NHCOCH3 ; and R12 is substituted or unsubstituted aryl or aryl lower alkyl. In this embodiment, R1 can be NH2; R3 can be CH2 ; R5 can be CO; R9 can be H; and R12 can be substituted or unsubstituted phenyl or benzyl, wherein said substituent is lower alkyl or halo.
Examples of the present invention include the following: ##STR3##
The compounds of the present invention may have asymmetric centers and occur as racemates, racemic mixtures, and as individual diastereomers, with all possible isomers, including optical isomers, being included in the present invention. For simplicity, where no specific configuration is depicted in the structural formulae, it is understood that all enantiometric forms and mixtures thereof are represented.
As used herein, "lower alkyl" is intended to include saturated aliphatic hydrocarbon groups having 1-6 carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, and the like. "Lower alkoxy" groups include those groups having 1-6 carbons. Examples of lower alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, and the like. All alkyl and alkoxy groups may be branched or straight chained, but are noncyclic. The term "cycloalkyl" means a 3-7 carbon ring. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloseptyl. The term "halo" means chloro, bromo, iodo, or fluoro. The terms "heterocycle lower alkyl," "thio lower alkyl," "cycloalkyl lower alkyl", and "aryl lower alkyl," are substituted, respectively, with one to three heterocycle, thio, cycloalkyl, and aryl groups.
As used herein, "aryl" is intended to include any stable monocyclic, bicyclic, or tricyclic carbon ring(s) of up to 7 members in each ring, wherein at least one ring is aromatic. Examples of aryl groups include phenyl, naphthyl, anthracenyl, biphenyl, tetrahydronaphthyl, indanyl, phenanthrenyl, and the like.
The term heterocycle, as used herein, represents a stable 5- to 7-membered monocyclic or stable 8- to 11-membered bicyclic or stable 11 to 15-membered tricyclic heterocyclic ring which is either saturated or unsaturated, and which consists of carbon atoms and from one to four heteroatoms selected from the group consisting of N, O, and S, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring may be attached at any heteroatom or carbon atom which results in the creation of a stable structure. Examples of such heterocyclic elements include, but are not limited to, azepinyl, benzimidazolyl, benzisoxazolyl, benzofurazanyl, benzopyranyl, benzothiopyranyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, chromanyl, cinnolinyl, dihydrobenzofuryl, dihydrobenzothienyl, dihydrobenzothiopyranyl, dihydrobenzothio-pyranyl sulfone, furyl, imidazolidinyl, imidazolinyl, imidazolyl, indolinyl, indolyl, isochromanyl, isoindolinyl, isoquinolinyl, isothiazolidinyl, isothiazolyl, isothiazolidinyl, morpholinyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, piperidyl, piperazinyl, pyridyl, pyridyl N-oxide, quinoxalinyl, tetrahydrofuryl, tetrahydroisoquinolinyl, tetrahydro-quinolinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiazolyl, thiazolinyl, thiazolidinyl, thienofuryl, thienothienyl, thienyl, and the like.
When a group is substituted, it may be substituted one to four times. The various substituents may be attached to carbon atoms or to heteroatoms (e.g., S, N, or O).
As used herein, the term "residue of an α-amino acid" stands for an α-amino acid residue which is either a natural α-amino acid which is found in nature (e.g., cysteinyl, methionyl, phenylalaninyl, leucinyl, etc.) or a synthetic α-amino acid which is not found in nature (e.g., neurleucyl or the residue of 1,2,3,4-tetrahydroisoguinoline-3-carboxylic acid or penicillamine, etc.).
The compounds of this invention can be provided in the form of pharmaceutically acceptable salts. Acceptable salts include, but are not limited to acid addition salts of inorganic acids such as acetate, maleate, fumarate, tartrate, succinate, citrate, lactate, methanesulfonate, p-toluenesulfonate, pamoate, salicylate, oxalate, and stearate. Also within the scope of the present invention, where applicable, are salts formed from bases such as sodium or potassium hydroxide. For further examples of pharmaceutically acceptable salts see, "Pharmaceutical Salts," J. Pharm. Sci. 66:1 (1977).
In another aspect, the invention features a method of inhibiting prenyl transferases (e.g., farnesyl transferase or geranylgeranyl transferase) in a subject, e.g., a mammal such as a human, by administering to the subject a therapeutically effective amount of a compound of formula I or formula II. In particular, the present invention also covers a method of treating restenosis or tissue proliferative diseases (i.e., tumor) in a subject by administering to the subject a therapeutically effective amount of a compound or its salt. Examples of a tissue proliferative disease include both those associated with benign (e.g., non-malignant) cell proliferation such as fibrosis, benign prostatic hyperplasia, atherosclerosis, and restenosis, and those associated with malignant cell proliferation, such as cancer (e.g., ras-mutant tumors). Examples of treatable tumors include breast, colon, pancreas, prostate, lung, ovarian, epidermal, and hematopoietic cancers (Sepp-Lorenzino, I, et al., Cancer Research 55:5302 (1995)).
A therapeutically effective amount of a compound of this invention and a pharmaceutically acceptable carrier substance (e.g., magnesium carbonate, lactose, or a phospholipid with which the therapeutic compound can form a micelle) together form a pharmaceutical composition (e.g., a pill, tablet, capsule, or liquid) for administration (e.g., orally, intravenously, transdermally, or subcutaneously) to a subject in need of the compound. The pill, tablet, or capsule can be coated with a substance capable of protecting the composition from the gastric acid or intestinal enzymes in the subject's stomach for a period of time sufficient to allow the composition to pass undigested into the subject's small intestine.
The dose of a compound of the present invention for treating the above-mentioned diseases or disorders varies depending upon the manner of administration, the age and the body weight of the subject, and the condition of the subject to be treated, and ultimately will be decided by the attending physician or veterinarian. Such an amount of the compound as determined by the attending physician or veterinarian is referred to herein as a "therapeutically effective amount."
Also contemplated within the scope of the invention are a method of preparing the compounds of formula I or formula II and the novel chemical intermediates used in these syntheses as described herein.
Other features and advantages of the present invention will be apparent from the detailed description of the invention and from the claims.
It is believed that one skilled in the art can, based on the description herein, utilize the present invention to its fullest extent. The following specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Also, all publications, patent applications, patents, and other references mentioned herein are incorporated by reference.
The following is a description of the synthesis of compounds 1, 4, and 9. Other compounds of the invention can be prepared in an analogous manner by a person of ordinary skill in the art.
The compounds of the invention were prepared using standard solution phase methodologies, e.g., as described in Greenstein, et al., Chemistry of the Amino Acids, Vols. 1-3 (J. Wiley, New York (1961)); and M. Bodanszky, et al., The Practice of Peptide Synthesis (Springer-Verlag, 1984)). The condensation reactions were carried out in an inert organic solvent, e.g., dimethylformide, dichloromethane, tetrahydrofuran, benzene or acetonitrile, using a suitable mild condensing agent, e.g., 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide-HCl (EDC, 0-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU), and optionally a catalyst, e.g., 1-hydroxybenzotriazole (HOBT). The reaction temperature was maintained below room temperature (-15°C to room temperature) in order to minimize side reactions. Cyclic disulfide formation was carried out under high dilute condition using iodine in various solvents (e.g., methanol, tetrahydrofuran (THF), acetic acid, water, etc.). B. Kamber, et al., Helv. Chim. Acta, 63(96):899 (1980). The intermediate and final products were isolated and purified by standard methods, e.g., column chromatography or HPLC. Compounds where R8, together with R9, forms CH2 CH2 can be made according to the methods of Williams, et al., J. Med. Chem. 39(7):1346 (1996), e.g., by starting with protected cysteine.
PAC N-[2-(R)-amino-3-mercaptopropyl]-L-penicillaminyl-1, 2,3,4-tetrahydro-3(s)-isoquinoline carbonyl methionine methylester cyclic disulfide (Compound 1)a) N-t-butoxycarbonyl-S-trityl-L-cysteinyl-N,O-dimethylamide
To an ice-cooled solution of N-t-butoxycarbonyl-L-cysteine (8.0 g) and N,O-dimethylhydroxylamine hydrochloride (7.1 g) in 80 ml dimethylformide was added 4.2 ml diethylcyanophosphonate and 14.7 ml diisopropylethylamine, and after stirring at 0°C for 1 hr, the reaction mixture was allowed to room temperature overnight. Volatile substances were removed in vacuo to dryness, and the residue was partitioned between ethylacetate and water. Ethylacetate layer was washed with aqueous NaHCO3, water, and dried (MgSO4). Solvent was evaporated in vacuo to dryness, and the residue was chromatographed on silica gel (165 g) using CHCl3 as an eluant. Appropriate fractions were pooled, and solvent was removed in vacuo to dryness. White foam 8.08 g TLC (silica gel: CHCl3 /acetone=9:1 Rf =0.58).
b) 2(R)-t-Butoxycarbonylamino-3-triphenylmethylmercapto-propanal
To an ice-cooled solution of N-t-Butoxycarbonyl 8-trityl-L-cysteinyl-N,O-dimethylamide (0.85 g) in 20 ml tetrahydrofuran (THF) was added dropwise 3 ml 1.0 M LiAH4 in THF under nitrogen atmosphere. After the mixture was stirred for 30 min. at 0°C, 1M KHSO4 was slowly added, and the resulting emulsion was filtered through celite pad and further washed with ethylacetate. After drying over anhydrous MgSO4, the solvent was removed in vacuo to dryness resulting in 0.7 g of the above-titled compound TLC (silica gel; CHCl3 /acetone=4:1; Rf=0.88).
c) N-t-butoxycarbonyl-S-acetamidomethylpenicillaminyl-1, 2,3,4-tetrahydro-3(S)-isoquinolinecarbonyl-methionine methylester
To an ice-cooled solution of N-t-butoxycarbonyl-L-1, 2,3,4-tetrahydro-3(S)-isoquinoline (2.77 g) and L-methionine methylester hydrochloride (2.0 g), 1-hydroxybenzotriazole (HOBT) (1.37 g) and O-Benzotriazol-l-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU) (3.87 g) in 30 ml dimethylformide was added 4.9 ml diisopropylethylamine (DIEA). After stirring at 0°C for 30 min, the reaction mixture was allowed to room temperature overnight. Volatile substances were evaporated in vacuo to dryness, and the residue was partitioned between EtOAc and water. EtOAc layer was washed with aqueous NaHCO3, water, and dried (MgSO4). Solvent was evaporated in vacuo to dryness. It was treated with 50% trifluoracetic acid in chloroform (40 ml) containing 4.8 ml triethylsilane for 1 hour, and volatile substances were removed in vacuo to dryness. Trace of trifluoroacetic acid (TFA) was further evaporated with toluene. To the above L-1,2,3,4-tetrahydro-3(S)-isoquinolinecarbonyl methionine methylester TFA salt (2.2 g) in dichloromethane (20 ml) cooled to 0°C. was added 1.2 ml DIEA followed by a solution of HOBT (0.7 g), N-t-butoxycarbonyl-S-acetamidomethyl penicillin (1.6 g) in DMF (3 ml), and EDC (1.2 g). The mixture was stirred at 0°C for 30 min and then allowed to room temperature overnight. Volatile substances were removed in vacuo to dryness. The residue was partitioned between EtOAc and water. Ethylacetate layer was washed with aqueous NaHCO3, water, and then dried (MgSO4). Solvent was evaporated in vacuo to dryness to yield 3.3 g orange solid.
d) L-[S-acetamidomethylpenicillaminyl-1,2,3,4-tetrahydro-3[S]-isoquinolinecar bonyl methionine methylester and its TFA salt
N-t-butoxycarbonyl-S-acetamidomethyl-penicillaminyl-1,2,3,4-tetrahydro-3[S] -isoquinolinecarbonyl methionine methylester (3.3 g) was treated with 50% TFA in CH2 C12 (20 ml) containing 1 ml triethylsilane for 30 min. Volatile substances were removed in vacuo to dryness. Trace of TFA was removed by co-evaporation with toluene several times. The TFA salt was dissolved in CHCl3 (30 ml), treated with excess triethylamine, washed with water, dried (MgSO4), and solvent was evaporated in vacuo to give free base.
e) N-[2(R)-(t-butoxycarbonyl)amino-3-triphenylmethylmercapto-propyl]-L-[S-ace tamidomethyl-penicillaminyl]-1, 2,3,4-tetrahydro-3(S)-isoquinolinecarbonyl methionine methylester
To a solution of 2(R)-t-butoxycarbonylamino-3-triphenylmethyl-mercapto-propanal (0.7 g) and L-[S-acetamidomethylpenicillaminyl-1, 2,3,4-tetrahydro-3(s)-isoquinolinecarbonyl methionine methylester (0.43 g) in CH2 Cl2 (20 ml) containing 1% acetic acid was added triacetoxysodiumborohydride Na(OAc)3 BH (360 mg) in one portion. After stirring for 2 hours, the mixture was washed with water, 5% aqueous NaHCO3, water, and then dried (MgSO4). The solvent was evaporated in vacuo to dryness, and the residue was chromatographed on silica gel (50 g) using CHCl3 /acetone (19:1 to 9:1) as eluants. Appropriate fractions were pooled and solvents were removed in vacuo to dryness resulting in a white foam (390 mg) of the above title compound. TLC (silica gel; CHCl3 /acetone=4:1; Rf=0.4).
f) N-[2(R)-(t-butoxycarbonyl)amino-3-mercaptopropyl]-L-penicillaminyl]-1, 2,3,4-tetrahydro-3(S)-isoquinoline carbonyl methionine methylester cyclic disulfide
To a solution of N-[2(R)-(t-butoxycarbonyl)amino-3-triphenylmethylmercaptopropyl]-L-[S-acet amidomethyl-penicillaminyl]-1,2,3,4-tetrahydro-3(S)-isoquinoline carbonyl methionine methylester (500 mg) in 50 ml 90% aqueous MeOH was added dropwise a solution of iodine (250 mg) in methanol (MeOH) (10 ml). After stirring for 1 hour, most of methanol was removed in vacuo to a small volume, diluted with water, and extracted with ethylacetate. The ethylacetate extract was washed with water, aqueous Na2 S2 O3, water, and then dried (MgSO4). The solvent was evaporated in vacuo to dryness resulting in 400 mg of the above title compound.
g) N-[2-(R)-amino-3-mercaptopropyl]-L-penicillaminyl-1,2,3,4-tetrahydro-3(S)- isoquinoline carbonyl methionine methylester cyclic disulfide Crude N-[2(R)-(t-butoxycarbonyl)amino-3-mercaptopropyl]-L-penicillaminyl]-1,2,3, 4-tetrahydro-3(S)-isoquinoline carbonyl methionine methylester cyclic disulfide (400 mg) was treated with 90% trifluoroacetic acid (TFA) in water TFA/H2 O (9:1)(10 ml) for 30 min. Volatile substances were removed in vacuo to dryness, and a trace of TFA was evaporated with toluene several times and triturated with hexane, decanted, and then dried. Crude product was subjected to preparative high performance liquid chromatography (HPLC) using C18 column and 0.1% TFA and CH3 CN as mobile phase. Appropriate fractions were pooled, and solvents were removed giving the above title compound as a white solid (78 mg). M/e=541.1.
PAC N-[2-(R)-amino-3-mercaptopropyl]-L-[8-acetamidomethyl-penicillaminyl]-1,2,3 ,4-tetrahydro-3(S)-isoquinoline carbonyl methionine (Compound 4)To a solution of N-[2(R)-(t-butoxycarbonyl)-amino-3-triphenylmethylmercaptopropyl]-L-[s-ace tamidomethyl penicillaminyl]-1,2,3,4-tetrahydro-3(S)-isoquinolinecarbonyl methionine methylester (Example I e))(500 mg) in 10 MeOH (50 ml) was added 2 ml 2 N--NaOH. After 30 min., most of MeOH was removed in vacuo to a small volume, diluted with water, acidified with 5% aqueous citric acid, and extracted with ethylacetate. The ethylacetate extract was then dried (MgSO4). Solvent was evaporated in vacuo to dryness. The residue was treated with 50% TFA in CH2 C12 containing triethylsilane (Et3 SiH) (0.5 ml) for 40 min. Volatile substances were removed in dryness, and a trace of TFA was evaporated with toluene and then dried. Crude product was purified by prep. HPLC giving the above titled compound (100 mg) as a white solid. M/e=600.2
PAC N-[2-(R)-amino-3-mercaptopropyl]-L-penicillaminyl]-2,3-dimethylanilide cyclic disulfide (Compound 9)a) [N-t-Butoxycarbonyl-S-acetamidomethyl]penicillaminyl-2,3-dimethylanilide
To an ice-cooled solution of N-[t-butoxycarbonyl)-S-acetamidomethyl penicillamine (Bachem California, Torrance, Calif.) (0.64 g), 2,3-dimethylaniline (0.25 g), hydroxybenzotriazole (0.41 g) in dimethylformide (DMF)/CH2 Cl2 (1:1, 20 ml) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) (0.57 g). The mixture was stirred at 0-52C for 30 min. and then the temperature was slowly allowed to room temperature overnight. After evaporation of the solvents, the residue was partitioned between ethyl acetate (EtOAc) and water. EtOAc extract was washed with aqueous NaHCO3, water, and then dried (MgSO4). The solvent was evaporated in vacuo to dryness. The residue was chromatographed on silica gel (40 g) using CHCl3 /acetone=19:1 as eluants, appropriate fractions were pooled, and solvents were removed in vacuo to dryness giving 350 mg of the above titled compound. TLC (silica gel: CHCl3 /acetone=4:1, Rf-0.77).
b) L-[S-acetamidomethylpenicillaminyl-2,3-dimethyl anilide TFA salt
[N-t-butoxycarbonyl-S-acetamidomethyl]-penicillaminyl-2,3-dimethylanilide was treated with 50% TFA in CH2 Cl2 (20 ml) for 30 min. Volatile substances were removed in vacuo to dryness. Trace of TFA was removed by co-evaporation with toluene several times. The TFA salt was dissolved in CHCl3 (30 ml), treated with excess triethylamine, washed with water, dried (MgSo4), and solvent was evaporated in vacuo to give free base.
c) N-[2(R)-(t-butoxycarbonyl)amino-3-triphenylmethylmercapto propyl]-L-[S-acetamidomethylpenicillaminyl-2,3-dimethylamilide
To a stirred solution of 2(R)-t-butoxycarbonylamino-3-triphenylmethylmercaptopropanal (0.5 g; Example 1b) and L-[S-acetamidomethylpenicillaminyl-2,3-dimethylanilide TFA salt (0.3 g) in MeOH containing 1% acetic acid (HOAc) (10 ml) was added portionwise NaCNBH3 (100 mg). The mixture was stirred at room temperature overnight. Most of the solvent was evaporated in vacuo to a small volume, which was partitioned between EtOAc and water. EtOAc layer was further washed with aqueous NaHCO3, water, and then dried (MgSO4). After evaporation of solvent, the residue was chromatographed on silica gel (30 g) using CHCl3 -acetone (19:1 to 9:1) as eluants. Appropriate fractions were pooled, and solvents were evaporated in vacuo to dryness giving 360 mg of the above titled compound. TLC (silica gel: CHCl3 /acetone=9:1, Rf=0.13.
d) N-[2-(R)-amino-3-mercaptopropyl]-L-penicillaminyl]-2,3-dimethylamilide cyclic disulfide
To a stirred solution of N-[2(R)-(t-butoxycarbonyl) amino-3-triphenylmethylmercaptopropyl]-L-[S-acetamidomethyl penicillaminyl]-2,3-dimethylamilide (350 mg) in 50 ml 90% MeOH in water was added a solution of iodine (250 mg) in MeOH (5 ml). After 1 hour, most of the solvent was evaporated in vacuo to a small volume, diluted with water, extracted with EtOAc. EtOAc layer was washed with aqueous Na2 S2 O3, water, then dried (MgSO4). Solvent was removed in vacuo to dryness (220 mg), treated with 90% aqueous TFA (ml) for 30 min, and volatile substances were removed in vacuo to dryness. Crude product was purified by preparative HPLC giving 62 mg of the above titled compound as a white solid. M/e=340.2.
It is to be understood that while the invention has been described in conjunction with the detailed description thereof, that the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the claims.
| Patent | Priority | Assignee | Title |
| 10022364, | Aug 17 2015 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyltransferase inhibitors |
| 10292979, | Aug 17 2015 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyltransferase inhibitors |
| 10335404, | Aug 17 2015 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyltransferase inhibitors |
| 10471055, | Aug 17 2015 | KURA ONCOLOGY, INC | Methods of treating cancer patients with farnesyltransferase inhibitors |
| 11124839, | Nov 03 2016 | KURA ONCOLOGY, INC | Methods of treating cancer patients with farnesyltransferase inhibitors |
| 11207314, | Aug 17 2015 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyltransferase inhibitors |
| 5299915, | Jul 15 1992 | General Electric Company | Bucket for the last stage of a steam turbine |
| 7932036, | Mar 12 2008 | Janssen Diagnostics, LLC | Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase |
| 9707221, | Aug 17 2015 | Kura Oncology, Inc. | Methods of treating cancer patients with farnesyltransferase inhibitors |
| Patent | Priority | Assignee | Title |
| 5439918, | Mar 14 1994 | Merck Sharp & Dohme Corp | Inhibitors of farnesyl-protein transferase |
| 5491164, | Sep 29 1994 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| EP618221A2, | |||
| EP696593A2, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Jun 28 1996 | Biomeasure, Incorporated | (assignment on the face of the patent) | / | |||
| Aug 27 1996 | KIM, SUN H | Biomeasure Incorporated | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 008833 | /0372 | |
| Sep 05 2001 | Biomeasure, Incorporated | SOCIETE DE CONSEILS DE RECHERCHES ET D APPLICATIONS SCIENTIFIQUES, S A S | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 011935 | /0949 | |
| Nov 28 2008 | SOCIETE DE CONSEILS DE RECHERCHES ET D APPLICATIONS SCIENTIFIQUES, S A S | IPSEN PHARMA S A S | CHANGE OF NAME SEE DOCUMENT FOR DETAILS | 022240 | /0332 |
| Date | Maintenance Fee Events |
| Jun 18 2001 | ASPN: Payor Number Assigned. |
| Jun 18 2001 | M183: Payment of Maintenance Fee, 4th Year, Large Entity. |
| Dec 16 2005 | M1552: Payment of Maintenance Fee, 8th Year, Large Entity. |
| Jan 18 2010 | REM: Maintenance Fee Reminder Mailed. |
| Jun 16 2010 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
| Date | Maintenance Schedule |
| Jun 16 2001 | 4 years fee payment window open |
| Dec 16 2001 | 6 months grace period start (w surcharge) |
| Jun 16 2002 | patent expiry (for year 4) |
| Jun 16 2004 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Jun 16 2005 | 8 years fee payment window open |
| Dec 16 2005 | 6 months grace period start (w surcharge) |
| Jun 16 2006 | patent expiry (for year 8) |
| Jun 16 2008 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Jun 16 2009 | 12 years fee payment window open |
| Dec 16 2009 | 6 months grace period start (w surcharge) |
| Jun 16 2010 | patent expiry (for year 12) |
| Jun 16 2012 | 2 years to revive unintentionally abandoned end. (for year 12) |